NFE2L2 and pulmonary arterial hypertension: Nrf-2 activators attenuate experimental pulmonary hypertension (PH).15 Increased expression of Nox isoforms 1 and 4 in PAs has been demonstrated in experimental models of PH and in PASMCs from PAH patients.12 Cellular Src-related kinase (c-Src) is the predominant nonreceptor tyrosine kinase in the vasculature, which is required for regulation of Nox activity,16 and this may be dysregulated in PAs of PAH patients and experimental PH.17